nach oben

Erschienen in:

01.12.2024 | Review

Molecular Aspects of Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Salivary Gland

verfasst von: Raisa Ferreira Costa, Carolinne Alves de Oliveira, Ágatha Nagli de Mello Gomes, Silvia Vanessa Lourenço, Cláudia Malheiros Coutinho-Camillo

Erschienen in: Head and Neck Pathology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Salivary gland tumors (SGTs) are rare and highly heterogeneous lesions, making diagnosis a challenging activity. In addition, the small number of studies and samples evaluated difficults the determination of prognosis and diagnosis. Despite the solid advances achieved by research, there is still an intense need to investigate biomarkers for diagnosis, prognosis and that explain the evolution and progression of SGTs.

Methods

We performed a comprehensive literature review of the molecular alterations focusing on the most frequent malignant SGTs: mucoepidermoid carcinoma and adenoid cystic carcinoma.

Results

Due to the importance of biomarkers in the tumorigenenic process, this review aimed to address the mechanisms involved and to describe molecular and biomarker pathways to better understand some aspects of the pathophysiology of salivary gland tumorigenesis.

Conclusions

Molecular analysis is essential not only to improve the diagnosis and prognosis of the tumors but also to identify novel driver pathways in the precision medicine scenario.

Porccheri C, Meisel CT, Mitsiadis TA (2020) Molecular and Cellular Modelling of Salivary Gland Tumors Open New landscapes in diagnosis and treatment. Cancer 12:3107. https://doi.org/10.3390/cancers12113107CrossRef

Pedersen AML, Sørensen CE, Proctor GB, Carpenter GH, Ekström J (2018) Salivary secretion in health and disease. J Oral Rehabil 45:730–746. https://doi.org/10.1111/joor.12664CrossRefPubMed

Ghannam MG, Singh P (2022) Anatomy, Head and Neck, salivary glands. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL)

El-Naggar AK, Chan JKC, Grandis JR et al (2017) WHO classification of head and neck tumours. In: World Health Organization classification of tumours. 4th edition. Lyon (France): International Agency for Research on Cancer (IARC), pp 163–84

Gatta G, Guzzo M, Locati LD, McGurk M, Prott FJ (2020) Major and minor salivary gland tumours. Crit Rev Oncol Hematol 152:102959. https://doi.org/10.1016/j.critrevonc.2020.102959CrossRefPubMed

Westergaard-Nielsen M, Godballe C, Eriksen JG et al (2021) Salivary gland carcinoma in Denmark: a national update and follow-up on incidence, histology, and outcome. Eur Arch Otorhinolaryngol 278:1179–1188. https://doi.org/10.1007/s00405-020-06205-2CrossRefPubMed

Pang J, Houlton JJ (2022) Management of malignant salivary gland conditions. SurgClin North Am 102:325–333. https://doi.org/10.1016/j.suc.2021.12.008CrossRef

Lima SS, Soares AF, de Amorim RF (2005) Epidemiologic profile of salivary gland neoplasms: analysis of 245 cases. Braz J Otorhinolaryngol 71. https://doi.org/10.1016/s1808-8694(15)31332-x. :335 – 40

10.

Kordzińska-Cisek I, Cisek P, Grzybowska-Szatkowska L (2020) The role of prognostic factors in salivary gland tumors treated by surgery and adjuvant radio- or chemoradiotherapy - A single Institution experience. CancerManag Res 12:1047–1067. https://doi.org/10.2147/CMAR.S233431CrossRef

11.

de Oliveira FA, Duarte EC, Taveira CT et al (2009) Salivary gland tumor: a review of 599 cases in a Brazilian population. Head Neck Pathol 3:271–275. https://doi.org/10.1007/s12105-009-0139-9CrossRefPubMedPubMedCentral

11.

Young A, Okuyemi OT (2022) Malignant salivary gland tumors. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL)

12.

Dos Santos ES, Rodrigues-Fernandes CI, Speight PM et al (2021) Impact of tumor site on the prognosis of salivary gland neoplasms: a systematic review and meta-analysis. Crit Rev Oncol/Hematol 162:103352. https://doi.org/10.1016/j.critrevonc.2021.103352CrossRefPubMed

13.

Nagano CP, Coutinho-Camillo CM, Pinto CA et al (2016) Cytokeratin immunoprofile of primary and metastatic adenoid cystic carcinoma of salivary glands: a report of two cases. Autops Case Rep 6:57–63. https://doi.org/10.4322/acr.2016.056CrossRefPubMedPubMedCentral

14.

Coca-Pelaz A, Rodrigo JP, Triantafyllou A et al (2015) Salivary mucoepidermoid carcinoma revisited. Eur Arch Otorhinolaryngol 272:799–819. https://doi.org/10.1097/01.pap.0000213058.74509.d3CrossRefPubMed

15.

Chen MM, Roman SA, Sosa JA et al (2014) Histologic grade as prognostic indicator for mucoepidermoid carcinoma: a population-level analysis of 2400 patients. Head Neck 36:158–163. https://doi.org/10.1002/hed.23256CrossRefPubMed

16.

Skalova A, Leivo I, Hellquist H et al (2021) High-grade Transformation/Dedifferentiation in Salivary Gland carcinomas: occurrence across subtypes and clinical significance. Adv Anat Pathol 28:107–118. https://doi.org/10.1097/PAP.0000000000000298CrossRefPubMed

17.

Hellquist H, Skálová A, Barnes L et al (2016) Cervical lymph Node Metastasis in High-Grade Transformation of Head and Neck Adenoid Cystic Carcinoma: a collective International Review. Adv Ther 33:357–368. https://doi.org/10.1007/s12325-016-0298-5CrossRefPubMedPubMedCentral

18.

Dillon PM, Petroni GR, Horton BJ et al (2017) A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma. Clin Cancer Res 23:4138–4145. https://doi.org/10.1158/1078-0432.CCR-16-2942CrossRefPubMedPubMedCentral

19.

Van Herpen C, Vander Poorten V, Skalova A et al (2022) Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment, and follow-up. ESMO Open 7:100602. https://doi.org/10.1016/j.esmoop.2022.100602CrossRefPubMedPubMedCentral

20.

Alfieri S, Granata R, Bergamini C et al (2017) Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm? Oral Oncol 66:58–63. https://doi.org/10.1016/j.oraloncology.2016.12.016CrossRefPubMed

21.

Cavalieri S, Mariani L, Vander Poorten V et al (2020) Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. Eur J Cancer 136:35–42. https://doi.org/10.1016/j.ejca.2020.05.013CrossRefPubMed

22.

Namboodiripad A (2014) A review: immunological markers for malignant salivary gland tumours. J Oral BiolCraniofac Res. https://doi.org/10.1016/j.jobcr.2014.05.003. 4:127 – 34CrossRef

23.

Meyer MT, Watermann C, Dreyer T et al (2021) 2021 update on diagnostic markers and translocation in salivary gland tumors. Int J MolSci 22:6771. https://doi.org/10.3390/ijms22136771CrossRef

24.

Byrd SA, Spector ME, Carey TE et al (2013) Predictors of recurrence and survival for head and neck mucoepidermoid carcinoma. Otolaryngol Head Neck Surg 149:402–408. https://doi.org/10.1177/0194599813489659CrossRefPubMedPubMedCentral

25.

Peraza A, Gómez R, Beltran J et al (2020) Mucoepidermoid carcinoma. An update and review of the literature. J Stomatol Oral Maxillofac Surg 121:713–720. https://doi.org/10.1016/j.jormas.2020.06.003CrossRefPubMed

26.

Cantù G (2021) Adenoid cystic carcinoma. An indolent but aggressive tumour. Part A: from a etiopathogenesis to diagnosis. ActaOtorhinolaryngolItal 41:206–214. https://doi.org/10.14639/0392-100X-N1379CrossRef

27.

He D, Zhu S, Zhao Q, Chang H, Li G, Shao Q, Zhang C, Wu P (2023) Epidemiology of and factors associated with overall survival for patients with head and neck adenoid cystic carcinoma. J Cancer Res Clin Oncol 149(15):14071–14080. https://doi.org/10.1007/s00432-023-05224-wCrossRefPubMed

28.

Califf RM (2018) Biomarker definitions and their applications. Exp Biol Med (Maywood) 243:213–221. https://doi.org/10.1177/1535370217750088

29.

Toper MH, Sarioglu S (2021) Molecular Pathology of Salivary Gland neoplasms: Diagnostic, Prognostic, and predictive perspective. Adv Anat Pathol 28:81–93. https://doi.org/10.1097/PAP.0000000000000291CrossRefPubMed

30.

Li A, Yang DH (2020) Application of immunohistochemistry in Basic and Clinical studies. Methods MolBiol 2108:43–55. https://doi.org/10.1007/978-1-0716-0247-8_4CrossRef

31.

Cleymaet R, Vermassen T, Coopman R et al (2022) The Therapeutic Landscape of Salivary Gland malignancies-where are we now? Int J MolSci 23:14891. https://doi.org/10.3390/ijms232314891CrossRef

32.

Adelstein DJ, Koyfman SA, El-Naggar AK et al (2012) Biology and management of salivary gland cancers. https://doi.org/10.1016/j.semradonc.2012.03.009. SeminRadiatOncol 22:245 – 53

33.

Ramos-Vara JA (2005) Technical aspects of immunohistochemistry. Vet Pathol 42:405–426. https://doi.org/10.1354/vp.42-4-405CrossRefPubMed

34.

Sukswai N, Khoury JD (2019) Immunohistochemistry innovations for diagnosis and tissue-based biomarker detection. CurrHematolMalig Rep 14. https://doi.org/10.1007/s11899-019-00533-9. :368 – 75

35.

Gao XL, Wu JS, Cao MX et al (2017) Cytokeratin-14 contributes to collective invasion of salivary adenoid cystic carcinoma. PLoS ONE 12:e0171341. https://doi.org/10.1371/journal.pone.0171341CrossRefPubMedPubMedCentral

36.

Teixeira LN, Janner ÉC, Teixeira T et al (2019) Comparison of p63/p40 expression with myoepithelial markers in minor salivary gland tumors. Int J SurgPathol 27:360–371. https://doi.org/10.1177/1066896918813678CrossRef

37.

Larsen SR, Bjørndal K, Godballe C, Krogdahl A (2012) Prognostic significance of Ki-67 in salivary gland carcinomas. J Oral Pathol Med 41:598–602. https://doi.org/10.1111/j.1600-0714.2012.01148.xCrossRefPubMed

38.

Bagulkar BB, Gawande M, Chaudhary M et al (2015) XIAP and Ki-67: a correlation BetweenAntiapoptotic and proliferative marker expression in Benign and Malignant tumours of salivary gland: an immunohistochemical study. J ClinDiagn Res 9:EC01–4. https://doi.org/10.7860/JCDR/2015/11690.5604CrossRef

39.

Warner KA, Adams A, Bernardi L et al (2013) Characterization of tumorigenic cell lines from the recurrence and lymph node metastasis of a human salivary mucoepidermoid carcinoma. Oral Oncol 49:1059–1066. https://doi.org/10.1016/j.oraloncology.2013.08.004CrossRefPubMed

40.

Belulescu IC, Mărgăritescu C, Dumitrescu CI et al (2020) Immunophenotypical alterations with impact on the epithelial-mesenchymal transition (EMT) process in salivary gland adenoid cystic carcinomas. Rom J MorpholEmbryol 61:175–187. https://doi.org/10.47162/RJME.61.1.20CrossRef

41.

Moore A, Bar Y, Maurice-Dror C et al (2020) Next-generation sequencing in salivary gland carcinoma: targetable alterations lead to a therapeutic advantage-multicenter experience. Head Neck 42:599–607. https://doi.org/10.1002/hed.26026CrossRefPubMed

42.

Rito M, Fonseca I (2018) Salivary gland neoplasms: does morphological diversity reflect Tumor Heterogeneity. Pathobiol 85:85–95. https://doi.org/10.1159/000479070CrossRef

43.

Ferrarotto R, Mitani Y, McGrail DJ et al (2021) Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas defines molecular subtypes and identifies therapeutic targets. Clin Cancer Res 27:852–864. https://doi.org/10.1158/1078-0432.CCR-20-1192CrossRefPubMed

44.

Even C, Lassen U, Merchan J et al (2020) Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. Invest New Drugs 38:402–409. https://doi.org/10.1007/s10637-019-00739-xCrossRefPubMed

45.

Majewska H, Gorczyński A, Czapiewski P et al (2021) ALK alterations in salivary gland carcinomas. Virchows Arch. https://doi.org/10.1007/s00428-020-02971-w. 478:933 – 41CrossRefPubMed

46.

Dos Santos ES, Ramos JC, Normando AGC et al (2020) Epigenetic alterations in salivary gland tumors. Oral Dis 26:1610–1618. https://doi.org/10.1111/odi.13253CrossRefPubMed

47.

Li Y, Gu F, He Y et al (2023) MicroRNA in adenoid cystic carcinoma (review). Int J Oncol 62:17. https://doi.org/10.3892/ijo.2022.5465CrossRefPubMed

48.

Salehinejad J, Mohtasham N, Bagherpour A et al (2014) Evaluation of c-kit protein (CD117) expression in common salivary gland neoplasms. J Oral Maxillofac Pathol 18:177–182. https://doi.org/10.4103/0973-029X.140732CrossRef

49.

Nishida H, Daa T, Kashima K et al (2015) KIT (CD117) expression in Benign and malignant sweat gland tumors. Am J Dermatopathol 37:898–805. https://doi.org/10.1097/DAD.0000000000000301CrossRefPubMedPubMedCentral

50.

Tariq H, Anjum S, Din HU et al (2017) Diagnostic utility of C-kit protein (CD117) expression in differentiating adenoid cystic carcinoma and polymorphous low-grade Adenocarcinoma. Pak J Med Sci 33:1376–1380. https://doi.org/10.12669/pjms.336.13373CrossRefPubMedPubMedCentral

51.

Tang YL, Fan YL, Jiang J et al (2014) C-kit induces epithelial-mesenchymal transition and contributes to salivary adenoid cystic cancer progression. Oncotarget 5:1491–1501. https://doi.org/10.18632/oncotarget.1606CrossRefPubMedPubMedCentral

52.

Phuchareon J, van Zante A, Overdevest JB et al (2014) c-Kit Expression is Rate-Limiting for Stem Cell Factor-Mediated Disease Progression in Adenoid Cystic Carcinoma of the Salivary Glands. Transl Oncol 7: 537 – 45. https://doi.org/10.1016/j.tranon.2014.07.006

53.

Hou H, Jia D, Yan W et al (2020) KIT/PDGFRA/KDR amplification defines a novel molecular subtype of adenoid cystic carcinoma patients who may benefit from treatment with tyrosine kinase inhibitors. Transl Cancer Res 9:4703–4714. https://doi.org/10.21037/tcr-20-637CrossRefPubMedPubMedCentral

54.

Freiberger SN, Brada M, Fritz C et al (2021) SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets. Neoplasia 23:473–487. https://doi.org/10.1016/j.neo.2021.03.008

55.

Fukai J, Fujita K, Yamoto T et al (2014) Intracranial extension of adenoid cystic carcinoma: potential involvement of EphA2 expression and epithelial-mesenchymal transition in tumor metastasis: a case report. BMC Res Notes 7:131. https://doi.org/10.1186/1756-0500-7-131CrossRefPubMedPubMedCentral

56.

Lorini L, Ardighieri L, Bozzola A et al (2021) Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma. Oral Oncol 115:105213. https://doi.org/10.1016/j.oraloncology.2021.105213CrossRefPubMed

57.

Ho AS, Ochoa A, Jayakumaran G et al (2019) Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. J Clin Invest 129:4276–4289. https://doi.org/10.1172/JCI128227CrossRefPubMedPubMedCentral

58.

Persson M, Andersson MK, Mitani Y, Brandwein-Weber MS, Frierson HF Jr, Moskaluk C, Fonseca I, Ferrarotto R, Boecker W, Loening T, El-Naggar AK, Stenman G (2022) Rearrangements, expression, and clinical significance of MYB and MYBL1 in adenoid cystic carcinoma: a multi-institutional study. Cancers (Basel) 14:3691. https://doi.org/10.3390/cancers14153691CrossRefPubMed

59.

Ferrarotto R, Mitani Y, Diao L et al (2017) Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic Carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. J Clin Oncol 35:352–360. https://doi.org/10.1200/JCO.2016.67.5264CrossRef

60.

Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, Kapoun AM, Xu L, Munster P (2018) A phase 1 dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol 29:1561–1568. https://doi.org/10.1093/annonc/mdy171CrossRefPubMed

61.

Karpinets TV, Mitani Y, Liu B et al (2021) Whole-genome sequencing of Common Salivary Gland carcinomas: Subtype-Restricted and Shared genetic alterations. Clin Cancer Res 27:3960–3969. https://doi.org/10.1158/1078-0432.CCR-20-4071CrossRefPubMedPubMedCentral

62.

Humtsoe JO, Kim HS, Jones L, Cevallos J, Boileau P, Kuo F, Morris LGT, Ha P (2022) Development and characterization of MYB-NFIB Fusion expression in Adenoid cystic carcinoma. Cancers (Basel) 14:2263. https://doi.org/10.3390/cancers14092263CrossRefPubMed

63.

Yan K, Yesensky J, Hasina R et al (2018) Genomics of mucoepidermoid and adenoid cystic carcinomas. Laryngoscope Investig Otolaryngol 3:56–61. https://doi.org/10.1002/lio2.139CrossRef

64.

Fujii K, Murase T, Beppu S et al (2017) MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma. Histopathology 71:823–834. https://doi.org/10.1111/his.13281CrossRefPubMed

65.

Shibata E, Morita KI, Kayamori K et al (2021) Detection of novel fusion genes by next-generation sequencing-based targeted RNA sequencing analysis in adenoid cystic carcinoma of head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol 132:426–433. https://doi.org/10.1016/j.oooo.2021.03.020CrossRefPubMed

66.

Yu GT, Bu LL, Zhao YY et al (2014) Inhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma. Am J Cancer Res 4:764–775PubMedPubMedCentral

67.

Chae YK, Chung SY, Davis AA et al (2015) Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget 6:37117–37134. https://doi.org/10.18632/oncotarget.5076CrossRefPubMedPubMedCentral

68.

Jiang LC, Huang SY, Zhang DS et al (2014) Expression of beclin 1 in primary salivary adenoid cystic carcinoma and its relation to Bcl-2 and p53 and prognosis. Braz J Med Biol Res 47:252–258. https://doi.org/10.1590/1414-431X20133231CrossRefPubMedPubMedCentral

69.

Nör F, Warner KA, Zhang Z et al (2018) Therapeutic inhibition of the MDM2-p53 Interaction prevents recurrence of adenoid cystic carcinomas. CQn Cancer Res 23:1036–1048. https://doi.org/10.1158/1078-0432.CCR-16-1235CrossRef

70.

Li Q, Huang P, Zheng C et al (2017) Prognostic significance of p53 immunohistochemical expression in adenoid cystic carcinoma of the salivary glands: a meta-analysis. Oncotarget 8:29458–29473. https://doi.org/10.18632/oncotarget.15297CrossRefPubMedPubMedCentral

71.

Humtsoe JO, Kim HS, Leonard B et al (2021) Newly identified members of FGFR1 splice variants engage in cross-talk with AXL/AKT Axis in Salivary Adenoid cystic carcinoma. Cancer Res 81:1001–1013. https://doi.org/10.1158/0008-5472.CAN-20-1780CrossRefPubMed

72.

Ettl T, Baader K, Stiegler C et al (2012) Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 106:719–726. https://doi.org/10.1038/bjc.2011.605CrossRefPubMedPubMedCentral

73.

Cao Y, Liu H, Xia SL et al (2019) PTEN downregulates WD repeat containing protein 66 in salivary adenoid cystic carcinoma. Oncol Rep 41:1827–1836. https://doi.org/10.3892/or.2018.6931CrossRefPubMed

74.

Guazzo E, Cooper C, Wilkinson L et al (2021) Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma. Head Neck 43:768–777. https://doi.org/10.1002/hed.26529CrossRefPubMed

75.

Wang WM, Zhao ZL, Zhang WF et al (2015) Role of hypoxia-inducible factor-1α and CD146 in epidermal growth factor receptor-mediated angiogenesis in salivary gland adenoid cystic carcinoma. Mol Med Rep 12:3432–3438. https://doi.org/10.3892/mmr.2015.3815CrossRefPubMedPubMedCentral

76.

Wang Y, Hu J, Wang Y et al (2018) EGFR activation induced snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells. Cell Cycle 17:1457–1470. https://doi.org/10.1080/15384101.2018.1489177CrossRefPubMedPubMedCentral

77.

Xia R, Zhou R, Tian Z et al (2013) High expression of H3K9me3 is a strong predictor of poor survival in patients with salivary adenoid cystic carcinoma. Arch Pathol Lab Med 137:1761–1769. https://doi.org/10.5858/arpa.2012-0704-OACrossRefPubMed

78.

Daa T, Kashima K, Kondo Y et al (2008) Aberrant methylation in promoter regions of cyclin-dependent kinase inhibitor genes in adenoid cystic carcinoma of the salivary gland. APMIS 116:21–26. https://doi.org/10.1111/j.1600-0463.2008.00773.xCrossRefPubMed

79.

Ling S, Rettig EM, Tan M et al (2016) Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening. Int J Oncol 49:225–234. https://doi.org/10.3892/ijo.2016.3532CrossRefPubMedPubMedCentral

80.

Brown AL, Al-Samadi A, Sperandio M et al (2019) MiR-455-3p, miR-150 and miR-375 are aberrantly expressed in salivary gland adenoid cystic carcinoma and polymorphous adenocarcinoma. J Oral Pathol Med 48:840–845. https://doi.org/10.1111/jop.12894CrossRefPubMed

81.

Andreasen S, Tan Q, Agander TK et al (2018) MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study. Virchows Arch 473:329–340. https://doi.org/10.1007/s00428-018-2423-0CrossRefPubMed

82.

Mitani Y, Roberts DB, Fatani H, Weber RS, Kies MS, Lippman SM, El-Naggar AK (2013) MicroRNA profiling of salivary adenoid cystic carcinoma: association of mir-17-92 upregulation with poor outcome. PLoS ONE 8:e66778. https://doi.org/10.1371/journal.pone.0066778CrossRefPubMedPubMedCentral

83.

Kerche LE, de Sousa EA, Squarize CH et al (2022) EMT in salivary gland tumors: the expression of microRNAs miR-155 and miR-200c is associated with clinical-pathological parameters. Mol Biol Rep 49:2157–2167. https://doi.org/10.1007/s11033-021-07033-1CrossRef

84.

Liu L, Hu Y, Fu J, Yang X, Zhang Z (2013) MicroRNA155 in the growth and invasion of salivary adenoid cystic carcinoma. J Oral Pathol Med 42(2):140–147. https://doi.org/10.1111/j.1600-0714.2012.01189.xCrossRefPubMed

85.

Kumar P, Kumawat RK, Uttam V et al (2023) The imminent role of microRNAs in salivary adenoid cystic carcinoma. Transl Oncol 27:101573. https://doi.org/10.1016/j.tranon.2022.101573CrossRef

86.

Xu B, Jungbluth AA, Frosina D et al (2019) The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. Histopathology 75:672–682. https://doi.org/10.1111/his.13944CrossRefPubMedPubMedCentral

87.

Harada K, Ferdous T, Ueyama Y (2018) PD-L1 expression in malignant salivary gland tumors. BMC Cancer 18:156. https://doi.org/10.1186/s12885-018-4069-3CrossRefPubMedPubMedCentral

88.

Mukaigawa T, Hayashi R, Hashimoto K et al (2016) Programmed death ligand-1 expression is associated with poor disease-free survival in salivary gland carcinomas. J Surg Oncol 114:36–43. https://doi.org/10.1002/jso.24266CrossRef

89.

Mosconi C, de Arruda JAA, de Farias ACR et al (2019) Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands. Oral Oncol 88:95–101. https://doi.org/10.1016/j.oraloncology.2018.11.028CrossRefPubMed

90.

Nakano T, Takizawa K, Uezato A et al (2019) Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas. Oral Oncol 90:30–37. https://doi.org/10.1016/j.oraloncology.2019.01.015CrossRefPubMed

91.

Morita M, Murase T, Okumura Y et al (2020) Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma. Histopathology 76:1013–1022. https://doi.org/10.1111/his.14100CrossRefPubMed

92.

Chen Z, Ni W, Li JL et al (2021) The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma. JCI Insight 6:e139497. https://doi.org/10.1172/jci.insight.139497CrossRefPubMedPubMedCentral

93.

Chen Z, Lin S, Li JL et al (2018) CRTC1-MAML2 fusion-induced lncRNA LINC00473 expression maintains the growth and survival of human mucoepidermoid carcinoma cells. Oncogene 37:1885–1895. https://doi.org/10.1038/s41388-017-0104-0CrossRefPubMedPubMedCentral

94.

Naakka E, Barros-Filho MC, Adnan-Awad S et al (2022) miR-22 and miR-205 Drive Tumor aggressiveness of Mucoepidermoid carcinomas of salivary glands. Front Oncol 11:786150. https://doi.org/10.3389/fonc.2021.786150CrossRefPubMedPubMedCentral

95.

Yoshimura T, Higashi S, Yamada S et al (2021) PCP4/PEP19 and HER2 are novel prognostic markers in Mucoepidermoid Carcinoma of the salivary gland. Cancers (Basel) 14:54. https://doi.org/10.3390/cancers14010054CrossRefPubMed

96.

Corrêa TS, Matos GDR, Segura M et al (2018) Second-line treatment of HER2-Positive salivary gland tumor: Ado-TrastuzumabEmtansine (T-DM1) after progression on Trastuzumab. Case Rep Oncol 11:252–257. https://doi.org/10.1159/000488669CrossRefPubMedPubMedCentral

97.

Nikolic N, Carkic J, IlicDimitrijevic I et al (2018) P14 methylation: an epigenetic signature of salivary gland mucoepidermoid carcinoma in the Serbian population. Oral Surg Oral Med Oral Pathol Oral Radiol 125:52–58. https://doi.org/10.1016/j.oooo.2017.09.013CrossRefPubMed

98.

Kang H, Tan M, Bishop JA et al (2017) Whole-exome sequencing of salivary gland Mucoepidermoid Carcinoma. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-16-0720. 23:283 – 88CrossRefPubMedPubMedCentral

99.

Lujan B, Hakim S, Moyano S, Nadal A, Caballero M, Diaz A, Valera A, Carrera M, Cardesa A, Alos L (2010) Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer 103:510–516. https://doi.org/10.1038/sj.bjc.6605788CrossRefPubMedPubMedCentral

100.

Binmadi NO, Basile JR, Perez P et al (2018) miRNA expression profile of mucoepidermoid carcinoma. Oral Dis 24:537–543. https://doi.org/10.1111/odi.12800CrossRefPubMed

101.

Flores BC, Lourenço SV, Damascena AS et al (2017) Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis. Virchows Arch 470:291–299. https://doi.org/10.1007/s00428-016-2049-zCrossRefPubMed

102.

Xu XF, Zhang TL, Jin S, Wang R, Xiao X, Zhang WD, Wang PY, Wang XJ (2013) Ardipusilloside I induces apoptosis by regulating Bcl-2 family proteins in human mucoepidermoid carcinoma Mc3 cells. BMC Complement Altern Med 13:322. https://doi.org/10.1186/1472-6882-13-322CrossRefPubMedPubMedCentral

103.

Choi SJ, Ahn CH, Hong KO et al (2021) Molecular mechanism underlying the apoptotic modulation by ethanol extract of Pseudolarixkaempferi in mucoepidermoid carcinoma of the salivary glands. Cancer Cell Int 21:427. https://doi.org/10.1186/s12935-021-02134-0CrossRefPubMedPubMedCentral

104.

BouZerdan M, Kumar PA, Zaccarini D et al (2023) Molecular targets in salivary gland cancers: a comprehensive genomic analysis of 118 mucoepidermoid carcinoma tumors. Biomedicines 11:519. https://doi.org/10.3390/biomedicines11020519CrossRef

105.

da Silva GM, Saavedra V, Ianez RCF et al (2019) Apoptotic signaling in salivary mucoepidermoid carcinoma. Head Neck 41:2904–2913. https://doi.org/10.1002/hed.25763CrossRefPubMed

106.

Bell D, Hanna EY (2012) Salivary gland cancers: biology and molecular targets for therapy. CurrOncol Rep. https://doi.org/10.1007/s11912-012-0220-5. 14:166 – 74CrossRef

107.

Chintakuntlawar AV, Okuno SH, Price K (2016) Systemic therapy for recurrent or metastatic salivary gland malignancies. Cancers Head Neck 1:11. https://doi.org/10.1186/s41199-016-0011-zCrossRefPubMedPubMedCentral

108.

Kurzrock R, Bowles DW, Kang H et al (2020) Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol 31:412–421. https://doi.org/10.1016/j.annonc.2019.11.018CrossRefPubMed

109.

Andersson MK, Afshari MK, Andrén Y et al (2017) Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid cystic carcinoma by inhibition of IGF1R/AKT signaling. J Natl Cancer Inst 109. https://doi.org/10.1093/jnci/djx017

110.

Su BH, Qu J, Song M, Huang XY, Hu XM, Xie J, Zhao Y, Ding LC, She L, Chen J, Lin LS, Lin X, Zheng DL, Lu YG (2014) NOTCH1 signaling contributes to cell growth, anti-apoptosis and metastasis in salivary adenoid cystic carcinoma. Oncotarget 5(16):6885–6895. https://doi.org/10.18632/oncotarget.2321CrossRefPubMedPubMedCentral

111.

Sajed DP, Faquin WC, Carey C, Severson EA, Afrogheh H, Johnson AA, Blacklow C, Chau SC, Lin NG, Krane DT, Jo JF, Garcia VY, Sholl JJ, Aster LM JC (2017) Diffuse staining for activated NOTCH1 correlates with NOTCH1 mutation status and is Associated with worse outcome in Adenoid cystic carcinoma. Am J Surg Pathol 41(11):1473–1482. https://doi.org/10.1097/PAS.0000000000000945CrossRef

112.

Jee KJ, Persson M, Heikinheimo K, Passador-Santos F, Aro K, Knuutila S, Odell EW, Mäkitie A, Sundelin K, Stenman G, Leivo I (2013) Genomic profiles and CRTC1-MAML2 fusion distinguish different subtypes of mucoepidermoid carcinoma. Mod Pathol 26(2):213–222. https://doi.org/10.1038/modpathol.2012.154CrossRef

113.

Andrews A, Warner K, Rodriguez-Ramirez C, Pearson AT, Nör F, Zhang Z, Kerk S, Kulkarni A, Helman JI, Brenner JC, Wicha MS, Wang S, Nör JE (2019) Ablation of Cancer Stem cells by therapeutic inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma. Clin Cancer Res 25(5):1588–1600. https://doi.org/10.1158/1078-0432.CCR-17-2730CrossRefPubMed

114.

Firwana B, Atassi B, Hasan R, Hasan N, Sukari A (2012) Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: case report and review of the literature. Avicenna J Med 2(3):71–73. https://doi.org/10.4103/2231-0770.102282CrossRefPubMedPubMedCentral

115.

Ferrarotto R, Mishra V, Herz E, Yaacov A, Solomon O, Rauch R, Mondshine A, Motin M, Leibovich-Rivkin T, Davis M, Kaye J, Weber CR, Shen L, Pearson AT, Rosenberg AJ, Chen X, Singh A, Aster JC, Agrawal N, Izumchenko E (2022) AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death Dis 13:678. https://doi.org/10.1038/s41419-022-05133-9CrossRefPubMedPubMedCentral

116.

Ferrarotto R, Sousa LG, Feng L, Mott F, Blumenschein G, Altan M, Bell D, Bonini F, Li K, Marques-Piubelli ML, Dal Lago EA, Johnson JJ, Mitani Y, Godoy M, Lee A, Kupferman M, Hanna E, Glisson BS, Elamin Y, El-Naggar A (2023) Phase II clinical trial of Axitinib and Avelumab in patients with Recurrent/Metastatic adenoid cystic carcinoma. J Clin Oncol 41:2843–2851. https://doi.org/10.1200/JCO.22.02221CrossRefPubMed

117.

Miranda EL, Stathis A, Hess D, Racca F, Quon D, Rodon J, Gadea OSS, Garcia JMP, Nuciforo P, Vivancos A, Cortes J, Ferrarotto R, Schönborn-Kellenberger O, Vigolo M, Bobadilla M, Beni L, Lehal R, Bauer MP, Vogl FD, Garralda E (2021) Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers. J Clin Oncol 39:3020–3020. https://doi.org/10.1200/JCO.2021.39.15_suppl.3020CrossRef

118.

Mishra V, Singh A, Chen X, Korzinkin M, Wing C, Sarkisova V, Ozerova A, Glushchenko O, Thodima V, Ito K, Scherle P, Lingen M, Hasina R, Pearson A, Rosenberg A, Zhavoronkov A, Ruggeri B, Agrawal N, Izumchenko E (2023) PRT543, a methyl transferase inhibitor, has potent anti-tumor activity against adenoid cystic carcinoma of salivary glands. Cancer Res 83:4897. https://doi.org/10.1158/1538-7445.AM2023-4897CrossRef

119.

Chung V, Wang L, Fletcher MS, Massarelli E, Reckamp KL, Cristea MC, Prajapati N, Parikh N, Whiting A, Wang RL, Wu M J (2019) First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma. J Clin Oncol 37:TPS3146–TPS3146. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS3146CrossRef

120.

Hu X, Zhang J, Liu R, Gao S, Qing Y, Yi S, Yuan J, Chen H, Fan B, Zheng H, Wang J (2021) Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors. J Clin Oncol 39:1024–1024. https://doi.org/10.1200/JCO.2021.39.15_suppl.1024CrossRef

Titel: Molecular Aspects of Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Salivary Gland
verfasst von: Raisa Ferreira Costa
Carolinne Alves de Oliveira
Ágatha Nagli de Mello Gomes
Silvia Vanessa Lourenço
Cláudia Malheiros Coutinho-Camillo
Publikationsdatum: 01.12.2024
Verlag: Springer US
Erschienen in: Head and Neck Pathology / Ausgabe 1/2024
Elektronische ISSN: 1936-0568
DOI: https://doi.org/10.1007/s12105-024-01629-2

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Molecular Aspects of Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Salivary Gland

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Xanthoma of the Jaw Bones: Cases Series and Review of Literature

Columnar Cell Thyroid Carcinoma: A Heterogeneous Entity Demonstrating Overlap Between Papillary Thyroid Carcinoma and Follicular Neoplasms

Odontoameloblastoma: A Distinct Entity?

Extramammary Paget Disease of Oral Mucosa: Case Report with Literature Review

Top IHC/ISH Hacks for and Molecular Surrogates of Poorly Differentiated Sinonasal Small Round Cell Tumors

Validation of the VisionArray® Chip Assay for HPV DNA Testing in Histology Specimens of Oropharyngeal Squamous Cell Carcinoma

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren